Current Health News Briefs: FDA Leadership Change, Vertex Trial Setback, & More
The U.S. FDA names Sean Keveney as chief counsel, overseeing legal matters. Vertex Pharmaceuticals faces setbacks after a trial failure for a pain drug. Florida reports 21 E. coli cases linked to raw milk. A Manhattan shooting raises CTE awareness. Chemours, DuPont, and Corteva settle NJ PFAS claims.
The U.S. Food and Drug Administration on Monday appointed Sean Keveney as its new chief counsel, with the responsibility of managing all legal affairs at the health agency. Previously, he served as acting general counsel at the Department of Health and Human Services.
Vertex Pharmaceuticals experienced a significant setback in its drug development efforts. Its shares tumbled 14.4% after the failure of a mid-stage trial for a non-opioid painkiller. The company will also halt a study for expanded use of an approved pain drug.
The Florida Department of Health reported 21 cases of E. coli linked to raw milk consumption. Meanwhile, a tragic Manhattan shooting heightens awareness of CTE in sports, and major chemical companies settle environmental claims with New Jersey for $875 million over PFAS pollution.
(With inputs from agencies.)
- READ MORE ON:
- FDA
- Sean Keveney
- Vertex Pharmaceuticals
- E.coli
- raw milk
- CTE
- PFAS
- Chemours
- DuPont
- NFL
Google News